HCB301 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 2023-3979 Solid Tumors

Pipeline

Phase 1: 1

Top Sponsors

FBD Biologics Limited1

Indications

Refractory Hodgkin Lymphoma1
Advanced Solid Tumor1
Cancer1

Greenville, South Carolina1 trial

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Prisma Health-Upstate

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.